ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)
South Korea
· Delayed Price · Currency is KRW 11,020
+630 (6.06%)
At close: Dec 5, 2025
ImmuneOncia Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Operating Revenue | 715.75 | 654.54 | 110 | 7,733 | 35.95 | 2.5 | Upgrade
|
| Other Revenue | - | - | - | - | 0 | - | Upgrade
|
| Revenue | 715.75 | 654.54 | 110 | 7,733 | 35.95 | 2.5 | Upgrade
|
| Revenue Growth (YoY) | 550.68% | 495.04% | -98.58% | 21413.29% | 1337.90% | 66.67% | Upgrade
|
| Cost of Revenue | 12.56 | 11.12 | 17.09 | 17.85 | 7.8 | 5.36 | Upgrade
|
| Gross Profit | 703.19 | 643.42 | 92.91 | 7,716 | 28.15 | -2.86 | Upgrade
|
| Selling, General & Admin | 7,799 | 4,964 | 5,038 | 7,662 | 5,075 | 2,958 | Upgrade
|
| Research & Development | 13,159 | 7,386 | 6,034 | 14,243 | 6,012 | 8,914 | Upgrade
|
| Amortization of Goodwill & Intangibles | 574.99 | 574.44 | 565.53 | 567.15 | 567.03 | 565.3 | Upgrade
|
| Other Operating Expenses | 36.44 | 19.64 | 19.55 | 15.15 | 12.63 | 3.3 | Upgrade
|
| Operating Expenses | 21,834 | 13,242 | 11,890 | 22,789 | 11,924 | 12,638 | Upgrade
|
| Operating Income | -21,131 | -12,599 | -11,797 | -15,073 | -11,896 | -12,641 | Upgrade
|
| Interest Expense | -5.53 | -6.93 | -3.13 | - | - | - | Upgrade
|
| Interest & Investment Income | 628.89 | 690.31 | 769.15 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -23.27 | -49.41 | 9.51 | 75.7 | 192.43 | 21.03 | Upgrade
|
| Other Non Operating Income (Expenses) | 11.29 | 6,278 | 19,886 | 11,507 | -48,783 | -6,528 | Upgrade
|
| EBT Excluding Unusual Items | -20,520 | -5,686 | 8,865 | -3,490 | -60,487 | -19,148 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.55 | -0.55 | -0.77 | -1.38 | -3.18 | -9.39 | Upgrade
|
| Pretax Income | -20,520 | -5,687 | 8,864 | -3,492 | -60,490 | -19,158 | Upgrade
|
| Net Income | -20,520 | -5,687 | 8,864 | -3,492 | -60,490 | -19,158 | Upgrade
|
| Net Income to Common | -20,520 | -5,687 | 8,864 | -3,492 | -60,490 | -19,158 | Upgrade
|
| Shares Outstanding (Basic) | 67 | 56 | 52 | 52 | 46 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 67 | 56 | 52 | 52 | 46 | 5 | Upgrade
|
| Shares Change (YoY) | 27.54% | 7.35% | 0.64% | 12.17% | 904.47% | -0.01% | Upgrade
|
| EPS (Basic) | -306.75 | -101.00 | 169.00 | -67.00 | -1302.00 | -4142.00 | Upgrade
|
| EPS (Diluted) | -306.75 | -101.00 | 169.00 | -67.00 | -1302.00 | -4142.00 | Upgrade
|
| Free Cash Flow | -18,632 | -14,750 | -8,766 | -15,337 | -2,078 | -10,322 | Upgrade
|
| Free Cash Flow Per Share | -278.52 | -261.96 | -167.13 | -294.29 | -44.72 | -2231.70 | Upgrade
|
| Gross Margin | 98.25% | 98.30% | 84.47% | 99.77% | 78.31% | -114.52% | Upgrade
|
| Operating Margin | -2952.31% | -1924.80% | -10724.51% | -194.91% | -33093.66% | -505642.37% | Upgrade
|
| Profit Margin | -2866.97% | -868.86% | 8058.20% | -45.15% | -168272.99% | -766313.44% | Upgrade
|
| Free Cash Flow Margin | -2603.11% | -2253.53% | -7968.93% | -198.32% | -5779.96% | -412888.34% | Upgrade
|
| EBITDA | -20,212 | -11,547 | -10,766 | -13,992 | -10,870 | -11,684 | Upgrade
|
| EBITDA Margin | - | - | - | -180.93% | - | - | Upgrade
|
| D&A For EBITDA | 919.5 | 1,051 | 1,031 | 1,081 | 1,026 | 956.83 | Upgrade
|
| EBIT | -21,131 | -12,599 | -11,797 | -15,073 | -11,896 | -12,641 | Upgrade
|
| EBIT Margin | - | - | - | -194.91% | - | - | Upgrade
|
| Advertising Expenses | - | 1 | 1 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.